Focusing on Improving Patient Outcomes for Serious Unmet Medical Needs
Latest News
News / 06 May 2021
Summit Therapeutics Publishes Scientific Updates to Corporate Website
News / 05 May 2021
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
News / 21 Apr 2021
Summit Therapeutics Announces Commencement of Rights Offering
We are building a very differentiated company that focuses on bringing innovation to the treatment of high unmet medical needs by focusing on the cause of the condition and sparing the rest of the incredible ecosystem that is the human body. Precision-targeting agents will be the new standards of care because they benefit patients and healthcare providers by minimizing trauma while curing the disease, which, in turn, creates value for society and payers alike.
Chairman & Chief Executive Officer
Partners
BARDA
Summit is proud to partner with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), as initially announced on September 11, 2017, on its two Phase III pivotal trials, Ri-CoDIFy 1 & 2, investigating ridinilazole for the treatment and reduction of recurrence of C. difficile infection.